Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
TMO > SEC Filings for TMO > Form 8-K on 6-Dec-2013All Recent SEC Filings

Show all filings for THERMO FISHER SCIENTIFIC INC.

Form 8-K for THERMO FISHER SCIENTIFIC INC.


6-Dec-2013

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.

On December 4, 2013, Thermo Fisher Scientific Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Barclays Capital Inc., J.P. Morgan Securities LLC and RBS Securities Inc., as representatives of the several underwriters named in the Underwriting Agreement, for the issuance and sale by the Company of $900,000,000 aggregate principal amount of 1.30% Senior Notes due 2017 (the "2017 Notes"), $900,000,000 aggregate principal amount of 2.40% Senior Notes due 2019 (the "2019 Notes"), $1,000,000,000 aggregate principal amount of 4.15% Senior Notes due 2024 (the "2024 Notes") and $400,000,000 aggregate principal amount of 5.30% Senior Notes due 2044 (the "2044 Notes", and together with the 2017 Notes, the 2019 Notes and the 2024 Notes, the "Notes"), in a public offering pursuant to a registration statement on Form S-3 (File No. 333-187080) and a related preliminary prospectus supplement and final prospectus supplement filed with the Securities and Exchange Commission (the "Offering").

The Company expects that the net proceeds from the sale of the Notes will be approximately $3.17 billion after deducting underwriting discounts and estimated offering expenses. The Company intends to use the anticipated net proceeds of the Offering to fund a portion of the cash consideration payable for the Company's acquisition of Life Technologies Corporation, a Delaware corporation (the "Life Technologies Acquisition"), which is estimated in the aggregate to amount to approximately $13.6 billion, and certain costs associated with the Life Technologies Acquisition. Depending on the timing of the closing of the Life Technologies Acquisition and the amount of cash available at that time, we will likely incur additional indebtedness to finance the balance of the purchase price, as described in the prospectus for the Offering.

The Notes will be issued pursuant to an indenture (the "Indenture"), dated as of November 20, 2009, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the "Trustee"), as supplemented by the Sixth Supplemental Indenture, to be dated as of December 11, 2013, between the Company and the Trustee.

The above description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

See Exhibit Index attached hereto.


  Add TMO to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for TMO - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.